Business Context and Reporting Period
Company: Relmada Therapeutics, Inc. (RLMD)
Filing Type: Form 8-K (Current Report)
Date of Report: October 15, 2019
Reporting Period: Specific event date (October 15, 2019)
Business Context: The filing discloses the release of top-line data from a Phase 2 clinical study for REL-1017 (dextromethadone) as an adjunctive treatment for treatment-resistant depression.
Key Financial Metrics
This Form 8-K is a disclosure of a specific corporate event and clinical trial results. It does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics. The filing text does not provide a clear value for any financial performance indicators.
Material Changes
There are no financial material changes reported in this filing. The material event is the completion and reporting of top-line data from the double-blind, placebo-controlled Phase 2 clinical study of REL-1017.
Guidance, Outlook, and Management Commentary
- Event: On October 15, 2019, the Company hosted a conference call to discuss the REL-1017 Phase 2 Results.
- Materials: A slide presentation (Exhibit 99.1) and a press release (Exhibit 99.2) detailing the results were issued.
- Regulatory Note: The information furnished in this Item 7.01 and the attached exhibits is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.
- Risks/Contingencies: No specific risks or contingencies are detailed in the text of this 8-K summary; investors are directed to the attached presentation and press release for full details on the clinical data.
Investor Verification Checklist
- Review Exhibit 99.1 (REL-1017 Phase 2 Presentation) for specific efficacy and safety data points.
- Review Exhibit 99.2 (Press Release) for the official summary of the Phase 2 results.
- Verify the Company's cash runway and funding status in the most recent 10-Q or 10-K, as this 8-K contains no financial data.
- Confirm the next steps for regulatory filings or Phase 3 trial planning based on the released data.